Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Cost-effectiveness evaluation of pioglitazone versus metformin and glibenclamide in the treatment of type 2 diabetes mellitus outpatients in the national institute “salvador subir

  • At: 2014 FIP Congress in Bangkok (Thailand)
  • Type: Poster
  • By: ALTAGRACIA-MARTíNEZ, Marina (Metropolitan Autonomous University Campus Xochimilco, Biological Systems, Mexico, Mexico)
  • Co-author(s): Cruz-Hernández, Carlos David (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
    González-García, Samuel (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
    Machorro-Rojas, Nancy (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
    Sánchez-Hernández, Gisela Monserrat (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
    Kravzov-Jinich, Jaime (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
  • Abstract:

    Introduction: In Mexico, type 2 diabetes mellitus (DM-2) is one of the leading causes of death.
    Aims: To evaluate the cost-effectiveness ratios of the pioglitazone, metformin and glibenclamide used in the treatment of outpatients with DM-2.
    Methods: Twenty-seven adult outpatients with DM-2 who were treated either with pioglitazone or metformin or..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses